Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.7 EUR | 0.00% | +2.78% | +17.09% |
May. 23 | FAES FARMA : Faes Farma is now receiving the long-awaited attention from investors | |
Apr. 26 | FAES FARMA : Q1 beat; full-year guidance re-affirmed |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The company is in a robust financial situation considering its net cash and margin position.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's earnings growth outlook lacks momentum and is a weakness.
- Most analysts recommend that the stock should be sold or reduced.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+17.09% | 1.25B | B | ||
+38.51% | 728B | C+ | ||
+33.05% | 603B | B | ||
-6.23% | 360B | C+ | ||
+18.78% | 332B | B- | ||
+1.35% | 279B | C+ | ||
+16.00% | 244B | B+ | ||
+8.09% | 207B | B- | ||
-5.77% | 205B | A+ | ||
+6.19% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- FAE Stock
- Ratings Faes Farma, S.A.